Sickle Cell DiseaseNCT06293222
Patient and Public Involvement and Engagement in Research With Children and Young People With Sickle Cell Disorder and Their Families
An observational study of Sickle Cell Disease, run by King's College London at 1 site in United Kingdom.
Trial summary
Aim: To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families. Read more about this study
- Who is it for?
- Ages 10 years and older
- Conditions the study is for
- Sickle Cell Disease
- How many people
- 20 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 21 Aug 2023to 30 Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 years and older
- All sexes
- Child, Adult, Older adult
Study population: * Group A: Members of a patient advocacy organisation (Sickle Cell Society n=5) * Group B: i) Children and young people (10-18 years) with sickle cell disorder (n=15) ii) their siblings (10-18 years, n=10) iii) their parents (n=15) * Group C: Researchers working with children with life-limiting or life changing conditions
Who may be able to join
- Group A: Members of a patient advocacy organisation (Sickle Cell Society n=5)
- Group B:
- Children and young people (10-18 years) with sickle cell disorder (n=15) ii) their siblings (10-18 years, n=10) iii) their parents (n=15)
- Group C: Researchers working with children with life-limiting or life changing conditions
Who cannot join
- Group A: Members of patient advocacy organisations other than the Sickle Cell Society
- Group B:
- Children and young people younger than ten years or older than 18 years and those without sickle cell disorder (n=15) ii) siblings younger than ten years or older than 18 years and without a brother or sister with sickle cell disorder iii) parents of children with conditions other than sickle cell disorder
- Group C: Researchers who do not have experience working with children with life-limiting or life changing conditions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Patient and Public Involvement and Engagement in Research on Life-limiting Conditions With Children and Young People With Sickle Cell Disorder and Their Families
Aim: To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families.
Methods: Workshops with a) members of a patient advocacy organisation (Sickle Cell Society n=5) b): i) Children and young people (10-18 years) with sickle cell disorder (n=15) and ii) their siblings (10-18 years, n=10) and iii) their parents (n=15), c) Researchers form the Cicely Saunders Institute Outputs: Resources that enable children and young people with sickle cell disorder and their families to engage in research
Read the detailed description
Aim:
To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families.
Objectives:
- Partner and collaborate with the Sickle Cell Society to continue to build on the work of the Cicely Saunders Institute to support a thriving Patient and Public Involvement and Engagement community that includes children and young people and their families
- Listen, hear, and understand what is important for children and young people with sickle cell disorder and provide them with the knowledge and skills to collaborate with researchers at the Cicely Saunders Institute during the design and implementation, analysis, and publication of research
- Equip staff within the Cicely Saunders Institute with the knowledge, understanding and awareness of the role children and young people with sickle cell disorder and their families can play in patient-involved research to ensure pathways for prioritizing and disseminating patient led research are realised
- Use data from objectives 1-3 to co-produce resources that may be used with a broader population of children and young people with serious and life-limiting conditions and their families to enable them to become equal partners in research
- Use learning from the proposed project with the Sickle Cell Society as an exemplar partnership, to inform future Patient and Public Involvement and Engagement with children and young people with other serious and life-limiting conditions including cancer and neuro-disabilities as the investigators expand the research remit at the Cicely Saunders Institute.
Background:
Public involvement must be diverse and inclusive to enable research that has the potential to reach those that stand to benefit from it the most, and thus to address issues of health equity and accessibility. Yet, long-standing evidence has shown that those most likely to be involved in research come from a narrow section of the population, from older age groups, white ethnic and higher socio-economic backgrounds. It is widely recognised that many groups are underserved and underrepresented in research.
Underserved groups include children, young people and adults from different minority ethnic groups, socio-economically disadvantaged groups, migrants, asylum seekers, people with mental health conditions and multiple health conditions. Children and young people, as a group have few opportunities for research involvement. There is also limited evidence on optimal models for partnerships in research.
Changing the balance of power and promoting wider participation, empowerment, diversity, and equality, are seen as neglected aspects of involvement that, if given due attention, can offer a way to move beyond involvement at the lowest levels of consultation to partnering and collaborating with a wider diversity of people and communities.
Methods:
Design: A sequential design involving three work packages
- WP1 will address Objectives 1 and 2: Apr-June 2023
The investigators will hold separate child and adult online/face to face scoping workshops (n=3) with:
Group B(i) children and young people with sickle cell disorder (n=15) and B(ii) their siblings (n=10) and B(iii) their parents (n=15) recruited via charity partners to:
(i) Explain what research is, how it is conducted, relevant policies and the mission statement of the Cicely Saunders Institute (ii) Review structures and processes for equitable and inclusive Patient and Public Involvement and Engagement for children and young people with sickle cell disorder and their families (iii) Identify relevant and appropriate training/education/skills needed to enable children and young people with sickle cell disorder and their families to engage in research.
The child and young people's workshop will be facilitated by an artist to assist with activities to engage participants. These workshops will be evaluated by those involved using surveys which will be administered at the end of the workshops.
- WP2 will address objective 3: Jul-Aug 2023 The investigators will hold online/face to face workshops (n=2) with researchers from the Cicely Saunders Institute (n=10) and members of Group B (n=10-15) to enable them to work together to identify resources needed for meaningful Patient and Public Involvement and Engagement with children and young people with sickle cell disorder and their families to take forward into WP3. These workshops will also be evaluated by those involved using surveys which will be administered at the end of the workshops.
- WP3 will address objectives 4 and 5: Sept-Dec 2023 Through a combination of online/face to face working groups (n=2), the investigators will work with children and young people with sickle cell disorder and their families (n=10-15 at each workshop) as well as researchers from the Cicely Saunders Institute (n=5) to co-produce resources that enable them to engage meaningfully in research incorporating the skills and knowledge identified in WP1. One of these workshops will be facilitated by an artist to help children develop their ideas into future resources for meaningful Patient and Public Involvement and Engagement. This will facilitate their involvement in future funding applications that are driven by them.
The investigators will have a final celebratory event with Group A: Sickle Cell Society and Groups B(i) children and young people with sickle cell disorder (n=15), Bii) their siblings (n=10) and Biii) their parents (n=15) to showcase achievements and plan next steps. The celebratory event will include an evaluation of the whole project.
Outputs:
WP1: (i) Partnership with a charity organisation, the Sickle Cell Society (ii) guidance on reaching minority ethnic groups and publicizing research opportunities; (iii) training skills analysis to enable children and young people with sickle cell disorder and their families to engage in research in a meaningful way.
WP2: Identification of resources needed to facilitate meaningful involvement of children and young people with sickle cell disorder and their families to engage in research WP3: (i) Resources that enable children and young people with sickle cell disorder and their families to engage in research (ii) a future strategy for meaningful Public Involvement and Engagement with children and young people with sickle cell disorder and their families (iii) an exemplar to inform future Patient and Public Involvement and Engagement with children and young people with other serious and life-limiting conditions including cancer and neuro-disabilities as the investigators expand the research remit.
- Conditions
- Sickle Cell Disease
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants with personal experience of sickle cell disorder. | Participants with personal experience of sickle cell disorder (parents, affected children or siblings). | |
| Researchers | Researchers working with children with life limiting or life changing conditions | |
| Members of a patient advocacy organisation | Members of a patient advocacy organisation (Sickle Cell Society) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Workshops with participants to develop resources that enable children and young people with sickle cell disorder and their families to engage in research
Resources that enable children and young people with sickle cell disorder and their families to engage in research
Measured: 8 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2024
- Study start21 Aug 2023
- Primary completion30 Apr 2024 (estimated)
- Study completion30 Apr 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sickle Cell DiseaseStudies of the same condition, open and under way.
- More trials run by King's College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- Sickle Cell Society
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06293222
- Sponsor's protocol ID
- SCD Support
- Status last verified
- Mar 2024
- First submitted
- 27 Feb 2024
- Last updated
- 7 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data from the study are likely to be made available on request from the CI. Data may not be publicly available due to ethical constraints.
Publications
Chudleigh J, Follett A, Mcfarlane-Griffith E, Abuo D, Josh, Imani, Holder P. Exploring How Children and Young People With Sickle Cell Disease and Their Families Want to be Involved in Research: A Qualitative Study. Health Expect. 2025 Apr;28(2):e70242. doi: 10.1111/hex.70242.
PubMed 40152512
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient and Public Involvement and Engagement in Research on Life-limiting Conditions With Children and Young People With Sickle Cell Disorder and Their Families
- ClinicalTrials.gov ID
- NCT06293222
- Acronym / sponsor ID
- SCD Support
- Conditions
- Sickle Cell Disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- Sickle Cell Society
- Study start
- 21 Aug 2023 (actual)
- Primary completion
- 30 Apr 2024 (estimated)
- Study completion
- 30 Apr 2024 (estimated)
- First posted
- 5 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim: To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families.
Methods: Workshops with a) members of a patient advocacy organisation (Sickle Cell Society n=5) b): i) Children and young people (10-18 years) with sickle cell disorder (n=15) and ii) their siblings (10-18 years, n=10) and iii) their parents (n=15), c) Researchers form the Cicely Saunders Institute Outputs: Resources that enable children and young people with sickle cell disorder and their families to engage in research
Detailed description
Aim:
To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families.
Objectives:
- Partner and collaborate with the Sickle Cell Society to continue to build on the work of the Cicely Saunders Institute to support a thriving Patient and Public Involvement and Engagement community that includes children and young people and their families
- Listen, hear, and understand what is important for children and young people with sickle cell disorder and provide them with the knowledge and skills to collaborate with researchers at the Cicely Saunders Institute during the design and implementation, analysis, and publication of research
- Equip staff within the Cicely Saunders Institute with the knowledge, understanding and awareness of the role children and young people with sickle cell disorder and their families can play in patient-involved research to ensure pathways for prioritizing and disseminating patient led research are realised
- Use data from objectives 1-3 to co-produce resources that may be used with a broader population of children and young people with serious and life-limiting conditions and their families to enable them to become equal partners in research
- Use learning from the proposed project with the Sickle Cell Society as an exemplar partnership, to inform future Patient and Public Involvement and Engagement with children and young people with other serious and life-limiting conditions including cancer and neuro-disabilities as the investigators expand the research remit at the Cicely Saunders Institute.
Background:
Public involvement must be diverse and inclusive to enable research that has the potential to reach those that stand to benefit from it the most, and thus to address issues of health equity and accessibility. Yet, long-standing evidence has shown that those most likely to be involved in research come from a narrow section of the population, from older age groups, white ethnic and higher socio-economic backgrounds. It is widely recognised that many groups are underserved and underrepresented in research.
Underserved groups include children, young people and adults from different minority ethnic groups, socio-economically disadvantaged groups, migrants, asylum seekers, people with mental health conditions and multiple health conditions. Children and young people, as a group have few opportunities for research involvement. There is also limited evidence on optimal models for partnerships in research.
Changing the balance of power and promoting wider participation, empowerment, diversity, and equality, are seen as neglected aspects of involvement that, if given due attention, can offer a way to move beyond involvement at the lowest levels of consultation to partnering and collaborating with a wider diversity of people and communities.
Methods:
Design: A sequential design involving three work packages
- WP1 will address Objectives 1 and 2: Apr-June 2023
The investigators will hold separate child and adult online/face to face scoping workshops (n=3) with:
Group B(i) children and young people with sickle cell disorder (n=15) and B(ii) their siblings (n=10) and B(iii) their parents (n=15) recruited via charity partners to:
(i) Explain what research is, how it is conducted, relevant policies and the mission statement of the Cicely Saunders Institute (ii) Review structures and processes for equitable and inclusive Patient and Public Involvement and Engagement for children and young people with sickle cell disorder and their families (iii) Identify relevant and appropriate training/education/skills needed to enable children and young people with sickle cell disorder and their families to engage in research.
The child and young people's workshop will be facilitated by an artist to assist with activities to engage participants. These workshops will be evaluated by those involved using surveys which will be administered at the end of the workshops.
- WP2 will address objective 3: Jul-Aug 2023 The investigators will hold online/face to face workshops (n=2) with researchers from the Cicely Saunders Institute (n=10) and members of Group B (n=10-15) to enable them to work together to identify resources needed for meaningful Patient and Public Involvement and Engagement with children and young people with sickle cell disorder and their families to take forward into WP3. These workshops will also be evaluated by those involved using surveys which will be administered at the end of the workshops.
- WP3 will address objectives 4 and 5: Sept-Dec 2023 Through a combination of online/face to face working groups (n=2), the investigators will work with children and young people with sickle cell disorder and their families (n=10-15 at each workshop) as well as researchers from the Cicely Saunders Institute (n=5) to co-produce resources that enable them to engage meaningfully in research incorporating the skills and knowledge identified in WP1. One of these workshops will be facilitated by an artist to help children develop their ideas into future resources for meaningful Patient and Public Involvement and Engagement. This will facilitate their involvement in future funding applications that are driven by them.
The investigators will have a final celebratory event with Group A: Sickle Cell Society and Groups B(i) children and young people with sickle cell disorder (n=15), Bii) their siblings (n=10) and Biii) their parents (n=15) to showcase achievements and plan next steps. The celebratory event will include an evaluation of the whole project.
Outputs:
WP1: (i) Partnership with a charity organisation, the Sickle Cell Society (ii) guidance on reaching minority ethnic groups and publicizing research opportunities; (iii) training skills analysis to enable children and young people with sickle cell disorder and their families to engage in research in a meaningful way.
WP2: Identification of resources needed to facilitate meaningful involvement of children and young people with sickle cell disorder and their families to engage in research WP3: (i) Resources that enable children and young people with sickle cell disorder and their families to engage in research (ii) a future strategy for meaningful Public Involvement and Engagement with children and young people with sickle cell disorder and their families (iii) an exemplar to inform future Patient and Public Involvement and Engagement with children and young people with other serious and life-limiting conditions including cancer and neuro-disabilities as the investigators expand the research remit.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Participants with personal experience of sickle cell disorder. | – | –Participants with personal experience of sickle cell disorder (parents, affected children or siblings). |
| Researchers | – | –Researchers working with children with life limiting or life changing conditions |
| Members of a patient advocacy organisation | – | –Members of a patient advocacy organisation (Sickle Cell Society) |
Who may qualify
- Ages
- 10 years and older
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- * Group A: Members of a patient advocacy organisation (Sickle Cell Society n=5) * Group B: i) Children and young people (10-18 years) with sickle cell disorder (n=15) ii) their siblings (10-18 years, n=10) iii) their parents (n=15) * Group C: Researchers working with children with life-limiting or life changing conditions
Key inclusion criteria (4 listed)
- Group A: Members of a patient advocacy organisation (Sickle Cell Society n=5)
- Group B:
- Group C: Researchers working with children with life-limiting or life changing conditions
Key exclusion criteria (4 listed)
- Group A: Members of patient advocacy organisations other than the Sickle Cell Society
- Group B:
- Group C: Researchers who do not have experience working with children with life-limiting or life changing conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Workshops with participants to develop resources that enable children and young people with sickle cell disorder and their families to engage in research
Time frame: 8 months
Resources that enable children and young people with sickle cell disorder and their families to engage in research
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2024.
- Derived from this study: PubMed 40152512Chudleigh J, Follett A, Mcfarlane-Griffith E, Abuo D, Josh, Imani, Holder P. Exploring How Children and Young People With Sickle Cell Disease and Their Families Want to be Involved in Research: A Qualitative Study. Health Expect. 2025 Apr;28(2):e70242. doi: 10.1111/hex.70242.
- Individual participant dataSharing planned: Undecided. Data from the study are likely to be made available on request from the CI. Data may not be publicly available due to ethical constraints.
Related trials for Sickle Cell Disease
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingPhase 1
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sickle Cell Disease, run by King's College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Workshops with participants to develop resources that enable children and young people with sickle cell disorder and their families to engage in research (time frame: 8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06293222, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2024.